ITRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Iterum Therapeutics PLC (ITRM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive momentum, has weak technical indicators, no significant news catalysts, and poor financial performance. It is better to wait for clearer signs of improvement before considering an investment.
The technical indicators for ITRM are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 41.677, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with resistance at 0.291 and support at 0.205.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The stock has shown a regular market price decline of -0.42% and a post-market decline of -0.08%. Financial performance is weak, with negative net income and declining EPS. Technical indicators are bearish, and there is no recent news or significant trading activity to drive positive sentiment.
In Q3 2025, revenue remained stagnant at $390,000 (0.00% YoY). Net income improved to -$8,979,000 (up 47.34% YoY), but EPS dropped by -33.33% to -0.2. Gross margin increased slightly to 5.38 (0.00% YoY). Overall, financial performance remains weak with no significant growth trends.
No data available for analyst ratings or price target changes.
